Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78230
Title:
Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases.
Authors:
Iczkowski, Kenneth A; Ferguson, Kevin L; Grier, David D; Hossain, Deloar; Banerjee, Saumitra S; McNeal, John E; Bostwick, David G
Abstract:
Adenoid cystic/basal cell carcinoma (ACBCC) of the prostate has been considered to have indolent biologic potential. However, outcome data are scant, with only one documented metastasis and death. We describe clinicopathologic features of ACBCC in 19 patients and document outcome in 15. Patients ranged in age from 43 to 83 years. All but one presented with urinary obstruction. ACBCC was diagnosed by transurethral resection in 15 cases, by needle biopsy in 3 cases, and unexpected in 1 case. Four patients had concurrent acinar adenocarcinoma. Histologically, cribriform or adenoid cystic patterns predominated in 12 cases and basal cell carcinoma pattern in 7. Five cases had prominent perineural invasion. ACBCC was immunoreactive for p63 and cytokeratins 7 and 34 beta E12 but not cytokeratin 20. After diagnosis, 5 patients underwent radical prostatectomy, 2 underwent pelvic exenteration, and the rest had no treatment. ACBCC showed extraprostatic extension in 5 cases and involved the bladder margin in 3. Metastases developed in 4 (21%) patients: liver (2), lung (2), bowel (1), and corpus cavernosum (1). In 15 cases with follow-up (0.3-11.8 years), two patients died of cancer (at 1.5 and 3 years after diagnosis), 3 remain alive with cancer, and 10 have no evidence of cancer. Thus, ACBCC of the prostate is a potentially aggressive neoplasm requiring ablative therapy.
Affiliation:
Veterans Affairs Medical Center, and Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32608-1197, uSA. iczkoka@pathology.ufl.edu
Citation:
Adenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. 2003, 27 (12):1523-9 Am. J. Surg. Pathol.
Journal:
The American Journal of Surgical Pathology
Issue Date:
Dec-2003
URI:
http://hdl.handle.net/10541/78230
PubMed ID:
14657711
Type:
Article
Language:
en
ISSN:
0147-5185
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorIczkowski, Kenneth A-
dc.contributor.authorFerguson, Kevin L-
dc.contributor.authorGrier, David D-
dc.contributor.authorHossain, Deloar-
dc.contributor.authorBanerjee, Saumitra S-
dc.contributor.authorMcNeal, John E-
dc.contributor.authorBostwick, David G-
dc.date.accessioned2009-08-21T14:39:24Z-
dc.date.available2009-08-21T14:39:24Z-
dc.date.issued2003-12-
dc.identifier.citationAdenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases. 2003, 27 (12):1523-9 Am. J. Surg. Pathol.en
dc.identifier.issn0147-5185-
dc.identifier.pmid14657711-
dc.identifier.urihttp://hdl.handle.net/10541/78230-
dc.description.abstractAdenoid cystic/basal cell carcinoma (ACBCC) of the prostate has been considered to have indolent biologic potential. However, outcome data are scant, with only one documented metastasis and death. We describe clinicopathologic features of ACBCC in 19 patients and document outcome in 15. Patients ranged in age from 43 to 83 years. All but one presented with urinary obstruction. ACBCC was diagnosed by transurethral resection in 15 cases, by needle biopsy in 3 cases, and unexpected in 1 case. Four patients had concurrent acinar adenocarcinoma. Histologically, cribriform or adenoid cystic patterns predominated in 12 cases and basal cell carcinoma pattern in 7. Five cases had prominent perineural invasion. ACBCC was immunoreactive for p63 and cytokeratins 7 and 34 beta E12 but not cytokeratin 20. After diagnosis, 5 patients underwent radical prostatectomy, 2 underwent pelvic exenteration, and the rest had no treatment. ACBCC showed extraprostatic extension in 5 cases and involved the bladder margin in 3. Metastases developed in 4 (21%) patients: liver (2), lung (2), bowel (1), and corpus cavernosum (1). In 15 cases with follow-up (0.3-11.8 years), two patients died of cancer (at 1.5 and 3 years after diagnosis), 3 remain alive with cancer, and 10 have no evidence of cancer. Thus, ACBCC of the prostate is a potentially aggressive neoplasm requiring ablative therapy.en
dc.language.isoenen
dc.subjectProstatic Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshAged, 80 and over-
dc.subject.meshCarcinoma, Adenoid Cystic-
dc.subject.meshCarcinoma, Basal Cell-
dc.subject.meshHumans-
dc.subject.meshImmunohistochemistry-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshPrecancerous Conditions-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshRetrospective Studies-
dc.subject.meshTreatment Outcome-
dc.subject.meshUrethral Obstruction-
dc.titleAdenoid cystic/basal cell carcinoma of the prostate: clinicopathologic findings in 19 cases.en
dc.typeArticleen
dc.contributor.departmentVeterans Affairs Medical Center, and Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32608-1197, uSA. iczkoka@pathology.ufl.eduen
dc.identifier.journalThe American Journal of Surgical Pathologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.